Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrochloric Acid Lock Therapy for CLABSI in Cancer and Hematologic Diseases
NCT05376566Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydrochloric acid in central line-associated bloodstream infection (CLABSI) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Treatment failure at 6 weeks. Started Jun 2022; status: completed.
02
Drugs
hydrochloric acid
03
Conditions
central line-associated bloodstream infection (CLABSI)
Beyond the preview
Go deeper on NCT05376566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376566.